...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Carve-Outs - revised
2
Dec 20, 2015 10:44AM
3
Dec 20, 2015 12:15PM

Koo, I agree completely. That's what I meant when I said that some people are getting ahead of themselves.

I am just trying to understand how the others who seem wrapped up in the 34.4 million might be thinking. F6's post on the other board on carve-outs seemed a valid explanation.

I did think of something else to ask at the Jan. 7th meeting though. It's been my experience that when companies talk about their operations, they generally do it in terms of their fiscal year. Both RVX and Zenith's fiscal years end April 30th, therefore their 3rd Quarter ends Jan. 31st.

Maybe someone can just confirm whether they speak in fiscal or calendar terms. That might help clear up some confusion and calm the frustration at the company supposedly not following through with their claims.

jmho

PVLee

Share
New Message
Please login to post a reply